Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claus Zehetner

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
The British Journal of Ophthalmology|February 7, 2013
Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedemaClaus Zehetner, Rudolf Kirchmair, Stefan Huber, et al.
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie|December 4, 2018
Triamcinolone in small-gauge vitrectomy for epiretinal membrane peelingReinhard Angermann, Claus Zehetner, Patrick Sidoroff, et al.
Ophthalmologica. Journal International D'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde|April 11, 2013
Reduced-fluence photodynamic therapy combined with ranibizumab for nonproliferative macular telangiectasia type 2Claus Zehetner, Gertrud Haas, Bernhard Treiblmayr, et al.
Journal of Ophthalmology|March 10, 2020
Effect of Timing on Visual Outcomes in Fovea-Involving Retinal Detachments Verified by SD-OCTReinhard Angermann, Nikolaos E Bechrakis, Teresa Rauchegger, et al.
Klinische Monatsblatter Fur Augenheilkunde|November 27, 2019
[Patient Mobility and Journey Distance as Risk Factors for Severe Visual Impairment: Real-Life Data Analysis of Treatment-naïve Patients with nAMD under Intravitreal Aflibercept Therapy]Teresa Rauchegger, Reinhard Angermann, Anja Meusburger, et al.
Journal of Ophthalmology|December 27, 2021
Effects of Intravitreal Aflibercept on the Systemic Insulin-like Growth Factor-I and Vascular Endothelial Growth Factor-A in Patients with Diabetic Retinopathy and Age-Related Macular DegenerationAnna Lena Huber, Reinhard Angermann, Yvonne Nowosielski, et al.
BMC Ophthalmology|September 19, 2022
Long-term persistence with aflibercept therapy among treatment-naïve patients with exudative age-related macular degeneration in a universal health care system: a retrospective studyReinhard Angermann, Alexander Franchi, Katharina Frede, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|July 10, 2019
Treatment compliance and adherence among patients with diabetic retinopathy and age-related macular degeneration treated by anti-vascular endothelial growth factor under universal health coverageReinhard Angermann, Teresa Rauchegger, Yvonne Nowosielski, et al.
Current Eye Research|November 28, 2017
Effects of Intravitreal Aflibercept on Galectin-1 and Vascular Endothelial Growth Factor-A Plasma Levels in Patients with Diabetic RetinopathyInga Waltl, Claus Zehetner, Christof Seifarth, et al.
Ocular Immunology and Inflammation|January 20, 2022
Two Cases of Acute Macular Neuroretinopathy Associated with the Adenovirus-based COVID-19 Vaccine Vaxzevria (Astrazeneca)Alexander Franchi, Teresa Rauchegger, Christoph Palme, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
The British Journal of Ophthalmology|February 7, 2013
Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedemaClaus Zehetner, Rudolf Kirchmair, Stefan Huber, et al.
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie|December 4, 2018
Triamcinolone in small-gauge vitrectomy for epiretinal membrane peelingReinhard Angermann, Claus Zehetner, Patrick Sidoroff, et al.
Ophthalmologica. Journal International D'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde|April 11, 2013
Reduced-fluence photodynamic therapy combined with ranibizumab for nonproliferative macular telangiectasia type 2Claus Zehetner, Gertrud Haas, Bernhard Treiblmayr, et al.
Journal of Ophthalmology|March 10, 2020
Effect of Timing on Visual Outcomes in Fovea-Involving Retinal Detachments Verified by SD-OCTReinhard Angermann, Nikolaos E Bechrakis, Teresa Rauchegger, et al.
Klinische Monatsblatter Fur Augenheilkunde|November 27, 2019
[Patient Mobility and Journey Distance as Risk Factors for Severe Visual Impairment: Real-Life Data Analysis of Treatment-naïve Patients with nAMD under Intravitreal Aflibercept Therapy]Teresa Rauchegger, Reinhard Angermann, Anja Meusburger, et al.
Journal of Ophthalmology|December 27, 2021
Effects of Intravitreal Aflibercept on the Systemic Insulin-like Growth Factor-I and Vascular Endothelial Growth Factor-A in Patients with Diabetic Retinopathy and Age-Related Macular DegenerationAnna Lena Huber, Reinhard Angermann, Yvonne Nowosielski, et al.
BMC Ophthalmology|September 19, 2022
Long-term persistence with aflibercept therapy among treatment-naïve patients with exudative age-related macular degeneration in a universal health care system: a retrospective studyReinhard Angermann, Alexander Franchi, Katharina Frede, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|July 10, 2019
Treatment compliance and adherence among patients with diabetic retinopathy and age-related macular degeneration treated by anti-vascular endothelial growth factor under universal health coverageReinhard Angermann, Teresa Rauchegger, Yvonne Nowosielski, et al.
Current Eye Research|November 28, 2017
Effects of Intravitreal Aflibercept on Galectin-1 and Vascular Endothelial Growth Factor-A Plasma Levels in Patients with Diabetic RetinopathyInga Waltl, Claus Zehetner, Christof Seifarth, et al.
Ocular Immunology and Inflammation|January 20, 2022
Two Cases of Acute Macular Neuroretinopathy Associated with the Adenovirus-based COVID-19 Vaccine Vaxzevria (Astrazeneca)Alexander Franchi, Teresa Rauchegger, Christoph Palme, et al.
Pageof 5